Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,973.50p on 18-06-2026 at 07:01:41
Change 1.00p 0.05%
Buy 1,974.00p
Sell 1,972.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 45.00 at 1,973.50p
Day's Volume: 49,116
Last Close: 1,972.50p
Open: 1,976.00p
ISIN: GB00BN7SWP63
Day's Range 1,970.50p - 1,978.50p
52wk Range: 1,315.00p - 2,282.00p
Market Capitalisation: £79.09b
VWAP: 1,975.34833p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 45 1,973.50p Automatic Execution
 08:01:35 - 18-Jun-26
Buy* 220 1,973.00p Automatic Execution
 08:01:30 - 18-Jun-26
Buy* 163 1,972.00p Automatic Execution
 08:01:15 - 18-Jun-26
Buy* 115 1,972.00p Automatic Execution
 08:01:15 - 18-Jun-26
Sell* 220 1,972.00p Automatic Execution
 08:01:15 - 18-Jun-26
Sell* 783 1,972.00p Automatic Execution
 08:01:15 - 18-Jun-26
Sell* 9 1,972.00p Automatic Execution
 08:01:15 - 18-Jun-26
Sell* 139 1,972.50p Automatic Execution
 08:01:15 - 18-Jun-26
Sell* 6 1,972.50p Automatic Execution
 08:01:15 - 18-Jun-26
Unknown* 0 1,974.50p SI Trade
 08:01:14 - 18-Jun-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
17th Jun 2026 (Wed) 1,948.50 1,974.00 1,935.50 1,972.50 4,713,165
16th Jun 2026 (Tue) 1,955.50 1,968.00 1,940.50 1,950.00 6,759,168
15th Jun 2026 (Mon) 1,984.00 1,988.50 1,953.50 1,958.00 7,052,610
12th Jun 2026 (Fri) 1,963.50 2,011.00 1,960.00 1,984.00 5,538,575
11th Jun 2026 (Thu) 1,914.00 1,973.00 1,910.50 1,962.50 7,722,952
10th Jun 2026 (Wed) 1,915.50 1,929.00 1,890.50 1,921.50 6,411,067
9th Jun 2026 (Tue) 1,888.00 1,912.00 1,839.00 1,903.50 9,721,895
8th Jun 2026 (Mon) 1,936.50 1,942.50 1,904.50 1,913.00 4,169,869
5th Jun 2026 (Fri) 1,915.50 1,940.00 1,908.00 1,938.00 6,350,731
4th Jun 2026 (Thu) 1,859.50 1,904.00 1,859.00 1,902.00 12,974,263
3rd Jun 2026 (Wed) 1,817.50 1,856.50 1,813.00 1,851.50 8,183,347
2nd Jun 2026 (Tue) 1,840.00 1,842.00 1,805.00 1,820.50 6,580,750
1st Jun 2026 (Mon) 1,866.00 1,882.00 1,832.50 1,842.50 4,511,279
29th May 2026 (Fri) 1,919.50 1,920.50 1,881.50 1,881.50 20,433,488
28th May 2026 (Thu) 1,921.50 1,935.50 1,905.50 1,918.00 6,885,741
27th May 2026 (Wed) 1,893.50 1,943.00 1,893.50 1,939.50 5,898,532
26th May 2026 (Tue) 1,931.50 1,942.50 1,900.00 1,925.00 5,172,404
25th May 2026 (Mon) 1,915.00 1,915.00 1,915.00 1,915.00 0
22nd May 2026 (Fri) 1,925.00 1,927.50 1,906.00 1,915.00 5,933,421
21st May 2026 (Thu) 1,894.00 1,919.00 1,882.00 1,914.50 3,471,573
20th May 2026 (Wed) 1,900.00 1,914.50 1,885.50 1,898.50 4,657,565
19th May 2026 (Tue) 1,879.00 1,909.00 1,872.00 1,902.00 4,650,637
18th May 2026 (Mon) 1,855.50 1,883.00 1,846.00 1,876.50 3,354,365
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
17th Jun 2026 4:06 pm RNS cUTI oral antibiotic Tebipenem approved by US FDA
15th Jun 2026 3:00 pm RNS Transaction in Own Shares
12th Jun 2026 7:00 am RNS Momelotinib orphan drug designations for VEXAS
11th Jun 2026 3:30 pm RNS Director/PDMR Shareholding
10th Jun 2026 3:30 pm RNS Director/PDMR Shareholding
9th Jun 2026 5:51 pm RNS Dr Hal Barron – New Directorship
9th Jun 2026 7:00 am RNS GSK enters agreement to acquire Nuvalent, Inc.
8th Jun 2026 3:00 pm RNS Transaction in Own Shares
1st Jun 2026 3:00 pm RNS Total Voting Rights
1st Jun 2026 3:00 pm RNS Transaction in Own Shares
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK says US FDA approves urinary tract infection treatment Utebzi

17th Jun 2026 21:36

(Alliance News) - GSK PLC and Spero Therapeutics Inc on Wednesday said that the US Food & Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections. Read More

GSK drug momelotinib gains regulatory nods as VEXAS treatment

12th Jun 2026 10:05

(Alliance News) - GSK PLC on Friday announced that momelotinib has received orphan drug designation from the US Food & Drug Administration, and the European Medicines Agency, to treat VEXAS syndrome. Read More

LONDON BRIEFING: UK economy contracts in April; Flutter to leave LSE

12th Jun 2026 07:58

(Alliance News) - The UK economy contracts 0.1% in April, Flutter Entertainment says it will delist from the London Stock Exchange in August, while Alternative Income REIT's largest shareholder makes a takeover bid. Read More

LONDON MARKET MIDDAY: FTSE 100 lags Europe as oil majors, GSK weigh

9th Jun 2026 12:10

(Alliance News) - Stock prices in London were mixed at midday on Tuesday, as the FTSE 100 lagged European peers despite renewed optimism for a peace deal in the Middle East, as oil majors and GSK weighed on the blue-chip index. Read More

WINNERS & LOSERS: GSK falls after Nuvalent buy; Molten Ventures jumps

9th Jun 2026 10:34

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,452.00
Change-56.61

Login to your account

Forgot Password?

Not Registered